Digital Platform Optimization for Heart Failure
(AIM-POWER Trial)
Trial Summary
What is the purpose of this trial?
This trial tests a software that helps doctors manage heart failure medications for patients with a specific type of heart failure. The software uses patient health data to recommend medication adjustments, aiming to reduce hospitalizations and deaths.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, it focuses on optimizing heart failure treatment, so your current medications might be adjusted.
What data supports the effectiveness of the treatment BiovitalsHF for heart failure?
The research highlights that heart failure management can be improved through the use of evidence-based therapies and monitoring systems, which reduce hospitalizations and mortality. Although BiovitalsHF is not directly mentioned, similar approaches in heart failure management have shown positive outcomes.12345
Is the digital platform for heart failure treatment safe for humans?
How is the treatment BiovitalsHF different from other heart failure treatments?
BiovitalsHF is unique because it uses a digital platform with artificial intelligence to support patient self-care, allowing patients to manage their heart failure more independently and personalize their treatment. This approach shifts from a one-size-fits-all model to a predictive, preventive, and personalized care strategy, potentially reducing hospitalizations and healthcare costs.1112131415
Research Team
Akshay Desai, MD
Principal Investigator
Brigham and Womens Hospital
Adam Devore, MD
Principal Investigator
Duke Clinical Research Institute
Eligibility Criteria
This trial is for adults with heart failure where the heart's left ventricle doesn't pump well (ejection fraction ≤ 40%). They should be on less than the recommended dose of medications for heart failure, diagnosed over 3 months ago, and have a functional class II-III. Excluded are those with significant other diseases, poor kidney function, very low blood pressure, severe lung issues or liver cirrhosis, among others.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants in the intervention arm are remotely monitored for 90 days using the BiovitalsHF platform to manage initiation and titration of GDMT
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- BiovitalsHF
Find a Clinic Near You
Who Is Running the Clinical Trial?
Biofourmis Inc.
Lead Sponsor